CAD usage in screening, diagnostic mammography increases: Study
September 23, 2015
Results from a Phase 1 clinical study evaluating tivozanib in combination with the mTOR inhibitor temsirolimus (Torisel), a rapamycin pro-drug, in patients with advanced kidney cancer will be presented in an oral session by Fairooz Kabbinavar, M.D., professor of medicine and urologic oncology, Henry Alvin and Carrie L. Meinhardt chair in Kidney Cancer Research, director, Hematology-Oncology Fellowship Program, medical director, Thoracic Oncology and Kidney Cancer Programs, David Geffen School of Medicine, University of California, Los Angeles. Study results showed tumor shrinkage in 12 out of 16 patients evaluated, and two partial responses as assessed by RECIST criteria. The combination was well-tolerated with no dose limiting toxicities (DLT).
Murray Robinson, Ph.D., senior vice president, translational medicine at AVEO, will also be making a presentation titled, "Tivozanib: clinical progress and response biomarkers," highlighting AVEO's ongoing tivozanib clinical research efforts, and the company's commitment to exploring how protein biomarker research may help clinicians determine optimal treatment combinations for patients battling kidney cancer and other tumor types.
"Understanding how predictive biomarkers fit into the kidney cancer landscape, and how they may help inform optimal treatment decisions for patients, is new and exciting ground for us in the oncology medical community," added Dr. Hutson. "I applaud AVEO's research efforts, and the company's goal of further advancing our understanding of how biomarkers may ultimately improve the treatment and care of patients living with kidney cancer."
Source : AVEO Pharmaceuticals, Inc.